Medindia

X

Ranbaxy Develops New Compound for Respiratory Inflammation

by Medindia Content Team on  April 3, 2007 at 4:17 PM Drug News   - G J E 4
Ranbaxy Develops New Compound for Respiratory Inflammation
Indian generics major, Ranbaxy Laboratories Limited has achieved a significant milestone in its collaboration with GSK.

The company's New Drug Discovery Research (NDDR) team has finished the development of a new compound for respiratory inflammation.
Advertisement

As per the recently signed multi-year agreement signed between the two companies in 2003, Ranbaxy will further profile this drug candidate through pre-clinical studies and take it through an Investigational New Drug (IND) application.

Advertisement
Ranbaxy will also be responsible for conducting phase I and phase II clinical studies through to proof of concept. GSK will then have the option to conduct further development through to final commercialization.

Dr Pradip Bhatnagar, Senior Vice President, New Drug Discovery, Ranbaxy, said, "A dynamic collaboration between GSK's CEEDD and Ranbaxy has been the key for this success. This achievement also reflects the discovery capabilities of Ranbaxy's research team and the growing partnership between the two organizations in the area of NCE research."

Ranbaxy could receive over $100 million in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales.

Source: BioSpectrum
SRM/L
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All

More News on: